{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:19:31Z","timestamp":1760242771509,"version":"build-2065373602"},"reference-count":91,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T00:00:00Z","timestamp":1463616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Pediatric Non-Hodgkin Lymphomas (NHL) are a diverse group of malignancies and as such treatment can vary based on the different biological characteristics of each malignancy. Significant advancements are being made in the treatment and outcomes of this group of malignancies. This is in large part due to novel targeted drug therapies that are being used in combination with traditional chemotherapy. Here, we discuss several new lines of therapy that are being developed or are in current use for pediatric patients with NHL.<\/jats:p>","DOI":"10.3390\/ph9020028","type":"journal-article","created":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T20:43:57Z","timestamp":1463690637000},"page":"28","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future"],"prefix":"10.3390","volume":"9","author":[{"given":"Caryn","family":"Sorge","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology\/Oncology, Children\u2019s Hospital of Alabama, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"McDaniel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology\/Oncology, Children\u2019s Hospital of Alabama, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Xavier","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology\/Oncology, Children\u2019s Hospital of Alabama, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of b cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: Mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin. Oncol."},{"key":"ref_3","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and chop chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-hodgkin\u2019s lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/sonc.2002.30151","article-title":"The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted epoch-r","volume":"29","author":"Wilson","year":"2002","journal-title":"Semin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult burkitt and burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"Chop-like chemotherapy plus rituximab versus chop-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the mabthera international trial (mint) group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2005-04-1570","article-title":"Dose-escalated chop plus etoposide (megachoep) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma","volume":"107","author":"Glass","year":"2006","journal-title":"Blood"},{"key":"ref_10","first-page":"314","article-title":"B-cell non-Hodgkin\u2019s lymphoma in children and adolescents: Surface antigen expression and clinical implications for future targeted bioimmune therapy: A children\u2019s cancer group report","volume":"1","author":"Perkins","year":"2003","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s00467-005-2013-7","article-title":"Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome","volume":"20","author":"Nozu","year":"2005","journal-title":"Pediatr. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/sj.bmt.1702792","article-title":"Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and rituximab","volume":"27","author":"Douglas","year":"2001","journal-title":"Bone Marrow Transp."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MOP.0b013e3282f424b0","article-title":"The efficacy of rituximab in high-grade pediatric B-cell lymphoma\/leukemia: A review of available evidence","volume":"20","author":"Attias","year":"2008","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pbc.20121","article-title":"Outcome of children with primary resistant or relapsed non-hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the austrian cooperative study group","volume":"44","author":"Attarbaschi","year":"2005","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2001.19.9.2390","article-title":"Outcomes of treatment of children and adolescents with recurrent non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children\u2019s cancer group study ccg-5912","volume":"19","author":"Kobrinsky","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood.V81.8.2003.2003","article-title":"Curability of relapsed childhood B-cell non-Hodgkin\u2019s lymphoma after intensive first line therapy: A report from the societe francaise d\u2019oncologie pediatrique","volume":"81","author":"Philip","year":"1993","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the children\u2019s oncology group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin\u2019s lymphoma and burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with stage III\/IV B-cell non-Hodgkin lymphoma: A children\u2019s oncology group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (\u226515 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: Results of the FAB LMB 96 study","volume":"30","author":"Cairo","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive burkitt lymphoma\/leukaemia: A children\u2019s oncology group report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","article-title":"Radioimmunotherapy of non-Hodgkin lymphomas","volume":"101","author":"Cheson","year":"2003","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5652s","DOI":"10.1158\/1078-0432.CCR-07-1060","article-title":"A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed\/refractory CD20-positive non-hodgkin\u2019s lymphoma: A children\u2019s oncology group study","volume":"13","author":"Krailo","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/modpathol.3800749","article-title":"D2\u201340 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: A comparative immunohistochemical study with kit (CD117) and CD30","volume":"20","author":"Lau","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_28","first-page":"319","article-title":"CD30-positive T-cell lymphomas co-expressing CD15: An immunohistochemical analysis","volume":"22","author":"Gorczyca","year":"2003","journal-title":"Int. J. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: A phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1097\/MPH.0b013e31828aff2c","article-title":"Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma","volume":"36","author":"Mikles","year":"2014","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10028","DOI":"10.1200\/jco.2013.31.15_suppl.10028","article-title":"Phase I\/II study of brentuximab vedotin in pediatric patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: Interim phase I safety data","volume":"31","author":"Neville","year":"2013","journal-title":"J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1182\/blood.V122.21.4378.4378","article-title":"Phase I\/II study of brentuximab vedotin in pediatric patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: Preliminary phase 2 data for brentuximab vedotin 1.8 mg\/kg in the hl study arm","volume":"122","author":"Locatelli","year":"2013","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2000.18.5.995","article-title":"Pharmacokinetics of nelarabine and 9-\u03b2-d-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies","volume":"18","author":"Kisor","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_38","first-page":"1135","article-title":"Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"3","author":"Cooper","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood-2003-01-0317","article-title":"Mechanisms for T-cell selective cytotoxicity of arabinosylguanine","volume":"102","author":"Rodriguez","year":"2003","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506u78) in children and young adults with refractory T-cell malignancies: A report from the children\u2019s oncology group","volume":"23","author":"Berg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","article-title":"Approval summary: Nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"12","author":"Cohen","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","article-title":"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma","volume":"150","author":"Commander","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2011.40.8724","article-title":"Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: A report from the children\u2019s oncology group","volume":"30","author":"Dunsmore","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/pbc.25470","article-title":"Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children\u2019s oncology group study aall0434","volume":"62","author":"Winter","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","article-title":"Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: A report from the berlin-frankfurt-muenster group","volume":"27","author":"Burkhardt","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pbc.21214","article-title":"Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/B:APPT.0000018797.66067.6c","article-title":"2-methoxyestardiol and bortezomib\/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating heat shock protein-27","volume":"9","author":"Chauhan","year":"2004","journal-title":"Apoptosis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor ps-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"ref_50","first-page":"1136","article-title":"The proteasome inhibitor ps-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.22456","article-title":"Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (all): A report from the therapeutic advances in childhood leukemia (TACL) consortium","volume":"55","author":"Messinger","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic advances in childhood leukemia & lymphoma (TACL) study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"key":"ref_53","first-page":"4460","article-title":"Novel mechanisms of apoptosis induced by histone deacetylase inhibitors","volume":"63","author":"Peart","year":"2003","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exphem.2004.09.008","article-title":"Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines","volume":"33","author":"Sakajiri","year":"2005","journal-title":"Exp. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jcb.20532","article-title":"Prospects: Histone deacetylase inhibitors","volume":"96","author":"Dokmanovic","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"ref_56","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncponc0106","article-title":"Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid","volume":"2","author":"Kelly","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/jco.2006.24.18_suppl.7500","article-title":"Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIB trial","volume":"24","author":"Olsen","year":"2006","journal-title":"J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.leukres.2012.02.021","article-title":"Histone deacetylase inhibition restores cisplatin sensitivity of hodgkin\u2019s lymphoma cells","volume":"36","author":"Kewitz","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1182\/blood-2010-05-284968","article-title":"Epigenetic silencing of bim in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition","volume":"116","author":"Bachmann","year":"2010","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1038\/bcj.2015.83","article-title":"Romidepsin targets multiple survival signaling pathways in malignant t cells","volume":"5","author":"Valdez","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.4161\/cc.9.9.11543","article-title":"Romidepsin (FK228\/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells","volume":"9","author":"Panicker","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2005.05808.x","article-title":"Childhood anaplastic large cell lymphoma has a high incidence of alk gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: A genetic and pathological correlation","volume":"131","author":"Perkins","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jcyt.2014.03.008","article-title":"Upregulation of nkg2d ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity","volume":"16","author":"Satwani","year":"2014","journal-title":"Cytotherapy"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous t-cell lymphoma: A case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral t-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Children\u2019s Oncology Group, Fouladi, M., Furman, W.L., Chin, T., Freeman, B.B., Dudkin, L., Stewart, C.F., Krailo, M.D., Speights, R., and Ingle, A.M. (2006). Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A children\u2019s oncology group report. J. Clin. Oncol., 24, 3678\u20133685.","DOI":"10.1200\/JCO.2006.06.4964"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II belief (CLN-19) study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Puvvada, S.D., Li, H., Rimsza, L.M., Bernstein, S.H., Fisher, R.I., LeBlanc, M., Schmelz, M., Glinsmann-Gibson, B., Miller, T.P., and Maddox, A.M. (2016). A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: Swog s0520. Leuk. Lymphoma, 1\u201311.","DOI":"10.3109\/10428194.2015.1135431"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","article-title":"Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer","volume":"68","author":"Choi","year":"2008","journal-title":"Cancer Res."},{"key":"ref_75","first-page":"2776","article-title":"Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors","volume":"59","author":"Griffin","year":"1999","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07399","article-title":"Oncogenic mutations of ALK kinase in neuroblastoma","volume":"455","author":"Chen","year":"2008","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1158\/0008-5472.CAN-14-1576","article-title":"Therapeutically targetable ALK mutations in leukemia","volume":"75","author":"Maxson","year":"2015","journal-title":"Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma","volume":"364","author":"Messa","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A children\u2019s oncology group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/1541-7786.MCR-14-0157","article-title":"Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma","volume":"13","author":"Ceccon","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and b-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1182\/blood.V126.23.5117.5117","article-title":"Ibrutinib significantly prolonged survival in a human burkitt lymphoma (BL) xenograft nsg mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL","volume":"126","author":"Lee","year":"2015","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1182\/blood.V126.23.4852.4852","article-title":"Ibrutinib alone and in combination with dexamethasone and carfilzomib signifiantly inhibits cell proliferation in primary mediastinal B-cell lymphoma (PMBL): Ibrutinib may be a future targeted agent in combination therapy in patients with PMBL","volume":"126","author":"Lee","year":"2015","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bartlett, N., LaPlant, B., Qi, J., Ansell, S., Kuruvilla, J., Reeder, C., Thye, L., Anderson, D., Erlichman, C., and Siegel, B. (2014, January 9). Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): Preliminary results of a phase 2 consortium (P2C) trial. Proceedings of the 56th ASH Annual Meeting and Exposition, San Francisco, CA, USA.","DOI":"10.1182\/blood.V124.21.800.800"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Fowler, N., Nastoupil, L., de Vos, S., Knapp, M., Flinn, I., Chen, R., Advani, R., Bhatia, S., Martin, P., and Mena, R. (2015, January 7). Ibrutinib plus rituximab in treatment-na\u00efve patients with follicular lymphoma: Results from a multicenter, phase 2 study. Proceedings of the 57th ASH Annual Meeting and Exposition, Orlando, FL, USA.","DOI":"10.1182\/blood.V126.23.470.470"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"Cal-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of b-cell malignancies, inhibits pi3k signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2146\/news140062","article-title":"Idelalisib approved for three blood cancers","volume":"71","author":"Traynor","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/9\/2\/28\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:24:08Z","timestamp":1760210648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/9\/2\/28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,19]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,6]]}},"alternative-id":["ph9020028"],"URL":"https:\/\/doi.org\/10.3390\/ph9020028","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2016,5,19]]}}}